Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.255 USD | -0.82% | -5.86% | -0.35% |
04-19 | US FDA mandates label updates on CAR-T cancer therapies | RE |
04-05 | Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication | MT |
Evolution of the average Target Price on 2seventy bio, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering 2seventy bio, Inc.
TD Cowen | |
Leerink Partners | |
Wedbush | |
Citigroup | |
Goldman Sachs | |
Guggenheim | |
Morgan Stanley | |
SVB Securities LLC | |
Canaccord Genuity | |
SVB Leerink | |
Cowen |
EPS Revisions
- Stock Market
- Equities
- TSVT Stock
- Consensus 2seventy bio, Inc.